Scolaris Content Display Scolaris Content Display

مقایسه تجویز زودهنگام اریتروپویتین در برابر تجویز تاخیری آن در درمان کم‌خونی در بیماری پیشرفته کلیه

Contraer todo Desplegar todo

Referencias

منابع مطالعات خارج‌شده از این مرور

Ir a:

Bahlmann 1991 {published data only}

Bahlmann J, Schoter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. Contributions to Nephrology 1991;88:90‐106. [MEDLINE: 2040200]CENTRAL

Bennett 1991 {published data only}

Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end‐stage renal disease. Journal of the American Society of Nephrology 1991;1(7):990‐8. [MEDLINE: 1883969]CENTRAL

Besarab 1998 {published data only}

Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin‐treated hemodialysis patients with cardiac disease. Kidney International 1999;56(1):253‐60. [MEDLINE: 10411700]CENTRAL
Berns JS, Rudnick MR, Cohen RM, Maloney A. Effect of normal v. anemic hematocrit on ambulatory blood pressure (ABP) in erythropoietin‐treated hemodialysis (HD) patients [abstract]. Journal of the American Society of Nephrology 1995;6(3):520. [CENTRAL: CN‐00483215]CENTRAL
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 1998;339(9):584‐90. [MEDLINE: 9718377]CENTRAL
Besarab A, Goodkin DA, Nissenson AR, Normal Hematocrit Cardiac Trial Authors. The normal hematocrit study‐‐follow‐up. New England Journal of Medicine 2008;358(4):433‐4. [MEDLINE: 18216370]CENTRAL
Conlon P, Kovalik E, Minda SN, Schumm D, Gutman R, Schwab SJ. Normalizing hematocrit in hemodialysis patients does not increase blood pressure [abstract]. Journal of the American Society of Nephrology 1995;6(3):526. [CENTRAL: CN‐00483579]CENTRAL
Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. Renal Failure 2000;22(2):205‐11. [MEDLINE: 10803764]CENTRAL
Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Renal Failure 2000;22(4):435‐44. [MEDLINE: 10901181]CENTRAL
Coyne DW. The health‐related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney International 2012;82(2):235‐41. [MEDLINE: 22437411]CENTRAL
Goodkin DA. The Normal Hematocrit Cardiac Trial revisited. Seminars in Dialysis 2009;22(5):495‐502. [MEDLINE: 19650856]CENTRAL
Kilpatrick R, Critchlow C, Besarab A, Fishbane S, Stehman‐Breen C, Krishnan M, et al. Epoetin alfa (EPO) responsiveness predicts survival in the normal hematocrit study (NHS) [abstract no: TH‐PO382]. Journal of the American Society of Nephrology 2006;17(Abstracts):188A. [CENTRAL: CN‐00615892]CENTRAL
Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman‐Breen C, Krishnan M, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(4):1077‐83. [MEDLINE: 18417744]CENTRAL

Canadian EPO Study 1990 {published data only}

Anonymous. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990;300(6724):573‐8. [MEDLINE: 2108751]CENTRAL
Anonymous. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. Canadian Erythropoietin Study Group. American Journal of Nephrology 1991;11(1):23‐6. [MEDLINE: 2048574]CENTRAL
Canadian Erythropoietin Study Group. A prospective randomized double‐blind study of re‐combinant human erythropoietin (r‐HuEPO) in chronic hemodialysis. [abstract]. Kidney International 1988;33(1):218. CENTRAL
Canadian Erythropoietin Study Group. The clinical effects and side‐effects of recombinant human erythropoietin (EPO) in anaemic patients on chronic hemodialysis [abstract]. Kidney International 1990;37(1):278. [CENTRAL: CN‐00583134]CENTRAL
Canadian Erythropoietin Study Group. The effect of recombinant human erythropoietin (EPO) upon quality of life and exercise capacity of anemic patients on chronic hemodialysis [abstract]. Kidney International 1990;37(1):278. [CENTRAL: CN‐00583135]CENTRAL
Keown PA. Quality of life in end‐stage renal disease patients during recombinant human erythropoietin therapy. The Canadian Erythropoietin Study Group. Contributions to Nephrology 1991;88:81‐9. [MEDLINE: 2040199]CENTRAL
Keown PA, Canadian Erythropoietin Study Group. The effect of recombinant human erythropoietin (EPO) upon quality of life (QL) and functional capacity (FC) of anemic patients on chronic hemodialysis [abstract]. Kidney International 1989;35(1):195. [CENTRAL: CN‐00583136]CENTRAL
Keown PA, Churchill DN, Poulin‐Costello M, Lei L, Gantotti S, Agodoa I, et al. Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. Hemodialysis International 2010;14(2):168‐73. [MEDLINE: 20345390]CENTRAL
Laupacis A. A randomized double‐blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group. Transplantation Proceedings 1991;23(2):1825‐6. [MEDLINE: 2053167]CENTRAL
Laupacis A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. The Canadian Erythropoietin Study Group. Seminars in Nephrology 1990;10(2 Suppl 1):11‐9. [MEDLINE: 2192412]CENTRAL
Laupacis A, Wong C, Churchill D. The use of generic and specific quality‐of‐life measures in hemodialysis patients treated with erythropoietin. The Canadian Erythropoietin Study Group. Controlled Clinical Trials 1991;12(4 Suppl):168S‐79S. [MEDLINE: 1663853]CENTRAL
Muirhead N, Keown P, Churchill DN, Lei L, Gitlin M, Mayne TJ. An intent‐to‐treat (ITT) analysis of anemia symptoms in the Canadian Erythropoietin Study Group (CESG) [abstract no: PUB537]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):932A. [CENTRAL: CN‐00790629]CENTRAL
Muirhead N, Keown P, Gitlin M, Mayne TJ, Churchill DN. A reanalysis of the Canadian Erythropoietin Study Group (CESG) patient‐reported outcomes (PRO) trial [abstract no: 177]. American Journal of Kidney Diseases 2008;51(4):A72. [CENTRAL: CN‐00790972]CENTRAL
Muirhead N, Keown P, Lei L, Gitlin M, Mayne TJ, Churchill D. The relationship between achieved hemoglobin (HB) & exercise tolerance [abstract no: 161]. American Journal of Kidney Diseases 2008;51(4):A68. [CENTRAL: CN‐00796608]CENTRAL
Muirhead N, Keown PA, Churchill DN, Poulin‐Costello M, Gantotti S, Lei L, et al. Dialysis patients treated with Epoetin alpha show improved exercise tolerance and physical function: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodialysis International 2011;15(1):87‐94. [MEDLINE: 21138518]CENTRAL
Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). Nephrology Dialysis Transplantation 1992;7(8):811‐6. [MEDLINE: 1325613]CENTRAL

Foley 2000 {published data only}

Foley RN, Parfrey PS, Morgan J, Barre P, Campbell P, Cartier P, et al. A randomized controlled trial of complete vs partial correction of anemia in hemodialysis patients with asymptomatic concentric lV hypertrophy or lV dilation [abstract no: A1064]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):208A. [CENTRAL: CN‐00445361]CENTRAL
Foley RN, Parfrey PS, Morgan J, Barre P, Campbell P, Cartier P, et al. Diastolic dysfunction in hemodialysis patients: the Canadian Normalization of Hemoglobin Study Group [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):261A. [CENTRAL: CN‐00550674]CENTRAL
Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney International 2000;58(3):1325‐35. [MEDLINE: 10972697]CENTRAL
Foley RN, Parfrey PS, Morgan J, Barre PE, Campbell P, Cartier P, et al. Hemoglobin levels and hospitalization in hemodialysis patients without symptomatic cardiac disease [abstract no: SA‐PO818]. Journal of the American Society of Nephrology 2002;13(September, Program & Abstracts):432A. [CENTRAL: CN‐00445362]CENTRAL
Wells GA, Coyne D, Lee KM, Foley RN, Parfrey PS, et al. Quality of life effects of normalization of hemoglobin in asymptomatic hemodialysis patients [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):230A. [CENTRAL: CN‐00448336]CENTRAL

Krivoshiev 2008 {published data only}

Krivoshiev S, Todorov VV, Manitius J, Czekalski S, Scigalla P, Koytchev R, et al. Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia. Current Medical Research & Opinion 2008;24(5):1407‐15. [MEDLINE: 18394266]CENTRAL
Wiecek A, Koytchev R, Ahmed I. Long‐term follow‐up safety study of epoetin zeta: post hoc subanalysis by age of patients with chronic kidney disease [abstract no: M596]. World Congress of Nephrology; 2009 May 22‐26; Milan, Italy. 2009. CENTRAL

Krivoshiev 2010 {published data only}

Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Pljesa S, Wolf‐Pflugmann M, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Advances in Therapy 2010;27(2):105‐17. [MEDLINE: 20369312]CENTRAL

Linde 2001 {published data only}

Danielson BG, Furuland H, Ahlmen J, Christensson A, Linde T, Strombom U. Scandinavian study of normalizing hemoglobin with rHu‐EPO in end stage renal failure [abstract no: A0822]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):160A. [CENTRAL: CN‐00550642]CENTRAL
Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre‐dialysis and dialysis patients. Nephrology Dialysis Transplantation 2003;18(2):353‐61. [MEDLINE: 12543892]CENTRAL
Furuland H, Linde T, Danielson BG. Cardiac function in patients with end‐stage renal disease after normalization of hemoglobin with erythropoietin (EPO) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):337A. [CENTRAL: CN‐00445402]CENTRAL
Furuland H, Linde T, Danielson BG. Dialysis adequacy after normalization of hemoglobin with erythropoietin (EPO) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):296A. [CENTRAL: CN‐00445403]CENTRAL
Furuland H, Linde T, Danielson BG. Physical exercise capacity in patients with end‐stage renal disease after normalizaton of hemoglobin with erythropoietin (EPO) [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):337A. [CENTRAL: CN‐00445404]CENTRAL
Furuland H, Linde T, Sandhagen B, Andren B, Wikstrom B, Danielson BG. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin‐alpha. Scandinavian Journal of Urology & Nephrology 2005;39(5):399‐404. [MEDLINE: 16257842]CENTRAL
Furuland H, Linde T, Wikstrom B, Danielson BG. Reduced hemodialysis adequacy after hemoglobin normalization with epoetin. Journal of Nephrology 2005;18(1):80‐5. [MEDLINE: 15772927]CENTRAL
Linde T, Ekberg H, Forslund T, Furuland H, Holdaas H, Nyberg G, et al. The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome. Transplantation 2001;71(1):79‐82. [MEDLINE: 11211199]CENTRAL
Linde T, Wahlberg J, Furuland H, Danielson BG. Results of renal transplantation in patients randomized to EPO treatment aimed to reach a subnormal or normal Hb [abstract]. Journal of the American Society of Nephrology 1998;9(Program & Abstracts):684A. [CENTRAL: CN‐00446408]CENTRAL
Strombom U, Ahlmen J, Danielsson B. The Scandinavian erythropoietin study: effects on quality of life of normalizing hemoglobin levels in uremic patients [abstract]. Journal of the American Society of Nephrology 1999;10(Program & Abstracts):269A. CENTRAL

Morris 1993 {published data only}

Morris KP, Sharp J, Watson S, Coulthard MG. Non‐cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Archives of Disease in Childhood 1993;69(5):580‐6. [MEDLINE: 8257180]CENTRAL
Morris KP, Skinner JR, Hunter S, Coulthard MG. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure. Archives of Disease in Childhood 1993;68(5):644‐8. [MEDLINE: 8323333]CENTRAL

Muirhead 1992 {published data only}

Muirhead N, Churchill DN, Goldstein M, Nadler SP, Posen G, Wong C, et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. American Journal of Nephrology 1992;12(5):303‐10. [MEDLINE: 1488998]CENTRAL

Nissenson 1995 {published data only}

Nissenson AR, Korbet S, Faber M, Burkart J, Gentile D, Hamburger R, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. Journal of the American Society of Nephrology 1995;5(7):1517‐29. [MEDLINE: 7703390]CENTRAL

Parfrey 2005 {published data only}

Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clinical Journal of the American Society of Nephrology: CJASN 2009;4(4):726‐33. [MEDLINE: 19339412]CENTRAL
Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(6):1669‐75. [MEDLINE: 18922988]CENTRAL
Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets, blood transfusions and quality of life in hemodialysis patients without symptomatic cardiac disease [abstract no: SA‐PO2745]. Journal of the American Society of Nephrology 2008;19(Abstracts Issue):730A. [CENTRAL: CN‐00756852]CENTRAL
Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clinical Journal of the American Society of Nephrology: CJASN 2010;5(5):805‐13. [MEDLINE: 20378644]CENTRAL
Foley RN, Parfrey PS, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D, et al. The effect of higher haemoglobin levels on left ventricular cavity volume in patients starting haemodialysis: a blinded, randomised, controlled trial in 596 patients without symptomatic cardiac disease [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:217. CENTRAL
Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double‐blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. Journal of the American Society of Nephrology 2005;16(7):2180‐9. [MEDLINE: 15901766]CENTRAL
Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D, et al. Double‐blind comparison of full and partial anemia correction with erythropoietin in incident hemodialysis patients without symptomatic heart disease [abstract no: PUB002]. Journal of the American Society of Nephrology 2004;15(Oct):762A. [CENTRAL: CN‐00583759]CENTRAL
Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D, et al. The effect of higher haemoglobin levels on quality of life in patients starting haemodialysis: a blinded, randomised, controlled trial in 596 patients without symptomatic cardiac disease [abstract]. 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15‐18; Lisbon, Portugal. 2004:229. CENTRAL

Park 2014 {published data only}

Park GS, Pollock A. Reduction of transfusions in dialysis patients taking epoetin alfa in a placebo‐controlled randomized clinical trial [abstract]. American Journal of Kidney Diseases 2014;63(5):A88. [EMBASE: 71448547]CENTRAL

Suzuki 1989 {published data only}

Suzuki M, Hirasawa Y, Hirashima K. Comparative dose study of recombinant human erythropoietin therapy in renal anaemia [abstract]. Nephrology Dialysis Transplantation 1988;3(4):503. [CENTRAL: CN‐00260383]CENTRAL
Suzuki M, Hirasawa Y, Hirashima K, Arakawa M, Odaka M, Ogura Y, et al. Dose‐finding, double‐blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end‐stage renal disease. Research Group for Clinical Assessment of rhEPO. Contributions to Nephrology 1989;76:179‐92. [MEDLINE: 2684520]CENTRAL

Trembecki 1995a {published data only}

Trembecki J, Kokot F, Wiecek A, Marcinkowski W, Rudka R. Improvement of sexual function in hemodialyzed male patients with chronic renal failure treated with erythropoietin (rHuEPO) [Poprawa czynnosci seksualnych u hemodializowanych mezczyzn chorych na przewlekla niewydolnosc nerek leczonych erytropoetyna (rHuEPO)]. Przeglad Lekarski 1995;52(9):462‐6. [MEDLINE: 8834648]CENTRAL

Wizemann 2008 {published data only}

Baldamus C, Krivoshiev S, Wolf‐Pflugmann M, Siebert‐Weigel M, Koytchev R, Bronn A. Long‐term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Advances in Therapy 2008;25(11):1215‐28. [MEDLINE: 18931828]CENTRAL
Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.[Erratum appears in Curr Med Res Opin. 2008 Oct;24(10):3007], [Erratum appears in Curr Med Res Opin. 2008 Apr;24(4):1155]. Current Medical Research & Opinion 2008;24(3):625‐37. [MEDLINE: 18208642]CENTRAL

Artunc 2007

Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrology Dialysis Transplantation 2007;22(10):2900‐8. [MEDLINE: 17556407]

Astor 2002

Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988‐1994). Archives of Internal Medicine 2002;162(12):1401‐8. [MEDLINE: 12076240]

Astor 2006

Astor BC, Coresh J, Heiss G, Pettitt D, Sarnak MJ. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. American Heart Journal 2006;151(2):492‐500. [MEDLINE: 16442920]

Bunn 2013

Bunn HF. Erythropoietin. Cold Spring Harbor Perspective in Medicine 2013;3(3):a011619. [MEDLINE: 23457296]

Chan 2013a

Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. [MEDLINE: 23303884]

Chan 2013b

Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza‐Jeric K, et al. SPIRIT 2013 statement: Defining standard protocol items for clinical trials. Annals of Internal Medicine 2013;158(3):200‐7. [MEDLINE: 23295957]

Del Vecchio 2010

Del Vecchio L, Locatelli F. Erythropoietin and iron therapy in patients with renal failure. Transfusion Alternatives in Transfusion Medicine 2010;11(1):20–9. [EMBASE: 2010285321]

Drueke 2006

Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 2006;335(20):2071‐84. [MEDLINE: 17108342]

EBPG 2004

Locatelli F, Aljama PA, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrology Dialysis Transplantation 2004;19 Suppl 2:ii1‐47. [MEDLINE: 15206425]

Elliott 2008

Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Experimental Hematology 2008;36(12):1573‐84. [MEDLINE: 18922615]

ERBP 2009

Locatelli F, Covic A, Eckardt K, Wiecek A, Vanholder R, ERA‐EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 2009;24(2):348‐54. [MEDLINE: 19037082]

ERBP 2010

Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC, et al. Target haemoglobin to aim for with erythropoiesis‐stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Study. Nephrology Dialysis Transplantation 2010;25(9):2846‐50. [MEDLINE: 20591813]

ERBP 2013

Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation 2013;28(6):1346‐59. [MEDLINE: 23585588]

Eschbach 1988

Eschbach JW, Adamson JW. Recombinant human erythropoietin: implications for nephrology. American Journal of Kidney Diseases 1988;11(3):203‐9. [MEDLINE: 3278599]

Eschbach 1989

Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney International 1989;35(1):134‐48. [MEDLINE: 2651751]

Finkelstein 2009

Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, et al. Health‐related quality of life and hemoglobin levels in chronic kidney disease patients. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(1):33‐8. [MEDLINE: 18987300]

Gabriel 2012

Gabriel SE, Normand SL. Getting the methods right ‐ the Foundation of Patient‐Centered Outcomes Research. New England Journal of Medicine 2012;367(9):787‐90. [MEDLINE: 22830434]

Gerson 2004

Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, et al. Anemia and health‐related quality of life in adolescents with chronic kidney disease. American Journal of Kidney Diseases 2004;44(6):1017‐23. [MEDLINE: 15558522]

Glaspy 2009

Glaspy JA. Erythropoietin in cancer patients. Annual Review of Medicine 2009;60:181‐92. [MEDLINE: 18980468]

Glassock 2009

Glassock RJ, Pecoits‐Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clinical Journal of The American Society of Nephrology: CJASN 2009;4 Suppl 1:S79‐91. [MEDLINE: 19996010]

Guyatt 2008

Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck‐Ytter Y, Schünemann HJ, et al. What is “quality of evidence” and why is it important to clinicians?. BMJ 2008;336(7651):995‐8. [MEDLINE: 18456631]

Halstenson 1991

Halstenson CE, Macres M, Katz SA, Schnieders JR, Watanabe M, Sobota JT, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology & Therapeutics 1991;50(6):702‐12. [MEDLINE: 1752115]

Hays 1997

Hays RD, Kallich JD, Mapes D, Coons SL, Amin N, Carter WB, et al. Kidney Disease Quality of Life Short Form (KDQOL‐SFTM), Version 1.3: A manual for use and scoring. 1997. www.rand.org/content/dam/rand/pubs/papers/2006/P7994.pdf (accessed 9 December 2015).

Higgins 2011

Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.

Horl 2013

Hörl WH. Differentiating factors between erythropoiesis‐stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73(2):117‐30. [MEDLINE: 23338536]

Ioannidis 2004

Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Annals of Internal Medicine 2004;141(10):781‐8. [MEDLINE: 15545678]

Jelkmann 2011

Jelkmann W. Regulation of erythropoietin production. Journal of Physiology 2011;589(Pt 6):1251‐8. [MEDLINE: 21078592]

Johansen 2010

Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ. Systematic review and meta‐analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis‐stimulating agents. American Journal of Kidney Diseases 2010;55(3):535‐48. [MEDLINE: 20133033]

Johansen 2012

Johansen KL, Finkelstein FO, Revicki DA, Evans C, Wan S, Gitlin M, et al. Systematic review of the impact of erythropoiesis‐stimulating agents on fatigue in dialysis patients. Nephrology Dialysis Transplantation 2012;27(6):2418‐25. [MEDLINE: 22187314]

Kainz 2010

Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo‐responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrology Dialysis Transplantation 2010;25(11):3701‐6. [MEDLINE: 20507852]

Kaufman 1998

Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. New England Journal of Medicine 1998;339(9):578‐83. [MEDLINE: 9718376]

KDIGO 2003

KDIGO. Kidney Disease: Improving Global Outcomes. kdigo.org/home/about‐us/ (accessed 9 December 2015).

KDIGO 2008

Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 2008;74(10):1237‐40. [MEDLINE: 18596731]

KDIGO 2012

Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney International ‐ Supplement 2012;2(4):279‐335. [DOI: 10.1038/kisup.2012.37]

KDOQI 2000

Anonymous. IV. NKF‐K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.[Erratum appears in Am J Kidney Dis 2001 Aug;38(2):442]. American Journal of Kidney Diseases 2001;37(1 Suppl 1):S182‐238. [MEDLINE: 11229970]

KDOQI 2006

KDOQI, National Kidney Foundation. II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. American Journal of Kidney Diseases 2006;47(5 Suppl 3):S16‐85. [MEDLINE: 16678661]

KDOQI 2007

KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. American Journal of Kidney Diseases 2007;50(3):471‐530. [MEDLINE: 17720528]

KDOQI 2014

National Kidney Foundation. KDOQI history. www.kidney.org/professionals/kdoqi/abouthistory.cfm (accessed 9 December 2015).

Levin 2002

Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney International ‐ Supplement 2002;61(Suppl 80):S35‐8. [MEDLINE: 11982810]

Locatelli 2004

Locatelli F, Pisoni RL, Combe C, Bommer J, Andreucci VE, Piera L, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).[Erratum appears in Nephrol Dial Transplant. 2004 Jun;19(6):1666]. Nephrology Dialysis Transplantation 2004;19(1):121‐32. [MEDLINE: 14671047]

Ly 2004

Ly J, Marticorena R, Donnelly S. Red blood cell survival in chronic renal failure. American Journal of Kidney Diseases 2004;44(4):715‐9. [MEDLINE: 15384023]

Macdougall 1999

Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. Journal of the American Society of Nephrology 1999;10(11):2392‐5. [MEDLINE: 10541299]

Macdougall 2006

Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clinical Journal of The American Society of Nephrology: CJASN 2006;1(6):1211‐5. [MEDLINE: 17699350]

McGonigle 1984

McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney International 1984;25(2):437‐44. [MEDLINE: 6727139]

Moher 2010

Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869. [MEDLINE: 20332511]

Moist 2013

Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. American Journal of Kidney Diseases 2013;62(5):860‐73. [MEDLINE: 24054466]

Padhi 2006

Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half‐life for darbepoetin alfa: results from a single‐dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clinical Pharmacokinetics 2006;45(5):503‐10. [MEDLINE: 16640455]

Palmer 2010

Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta‐analysis: erythropoiesis stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine 2010;153(1):23‐33. [MEDLINE: 20439566]

Parfrey 2009

Parfrey PS, Lauve M, Latremouille‐Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta‐analysis. Clinical Journal of The American Society of Nephrology: CJASN 2009;4(4):755‐62. [MEDLINE: 19339417]

PCORI 2012

Methodology Committee of the Patient‐Centered Outcomes Research Institute (PCORI). Methodological standards and patient‐centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012;307(15):1636‐40. [MEDLINE: 22511692]

Pfeffer 2009

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 2009;361(21):2019‐32. [MEDLINE: 19880844]

Phrommintikul 2007

Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta‐analysis. Lancet 2007;369(9559):381‐8. [MEDLINE: 17276778]

Rizzo 2010

Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Journal of Clinical Oncology 2010;28(33):4996‐5010. [MEDLINE: 20975064]

Ross 2002

Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health‐related quality‐of‐life domains: a systematic review. Clinical Therapeutics 2002;25(6):1786‐805. [MEDLINE: 12860499]

Schellekens 2008

Schellekens H. The first biosimilar epoetin: but how similar is it?. Clinical Journal of The American Society of Nephrology: CJASN 2008;3(1):174‐8. [MEDLINE: 18057303]

Sinclair 2013

Sinclair AM. Erythropoiesis stimulating agents: approaches to modulate activity. Biologics 2013;7:161‐74. [MEDLINE: 23847411]

Singh 2006

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine 2006;355(20):2085‐98. [MEDLINE: 17108343]

Tolman 2005

Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision‐support system: a randomized clinical study. Journal of the American Society of Nephrology 2005;16(5):1463‐70. [MEDLINE: 15788469]

Tonia 2012

Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD003407.pub5]

Turner 2012

Turner L, Shamseer L, Altman DG, Weeks L, Peters J, Kober T, et al. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.MR000030.pub2]

Vinhas 2012

Vinhas J, Barreto C, Assunção J, Parreira L, Vaz A. Treatment of anaemia with erythropoiesis‐stimulating agents in patients with chronic kidney disease does not lower mortality and may increase cardiovascular risk: a meta‐analysis. Nephron Clinical Practice 2012;121(3‐4):c95‐101. [MEDLINE: 23182871]

Weisbord 2008

Weisbord SD, Kimmel PL. Health‐related quality of life in the era of erythropoietin. Hemodialysis International 2008;12(1):6‐15. [MEDLINE: 18271834]

WHO 2008

Benoist B, McLean E, Egli I, Cogswell M. Worldwide prevalence of anaemia 1993‐2005: WHO Global Database on Anaemia. Geneva: World Health Organization, 2008. [ISBN: 978 92 4 159665 7]

Zhu 2006

Zhu X, Perazella MA. Nonhematologic complications of erythropoietin therapy. Seminars in Dialysis 2006;19(4):279‐84. [MEDLINE: 16893404]

Zoccali 2008

Zoccali C, Abramowicz D, Cannata‐Andia JB, Cochat P, Covic A, Eckardt KU, et al. European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation 2008;23(7):2162‐6. [MEDLINE: 18469309]

منابع دیگر نسخه‌های منتشرشده این مرور

Ir a:

Coronado Daza 2014

Coronado Daza J, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Urrútia G, Loza Munárriz C, et al. Early versus delayed erythropoietin for the anaemia of end‐stage kidney disease. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD011122]

Characteristics of studies

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Bahlmann 1991

RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Bennett 1991

Quasi‐RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Besarab 1998

Open‐label study investigating EPO alfa to achieve normal or low haematocrit

Canadian EPO Study 1990

RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Foley 2000

RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Krivoshiev 2008

RCT. Bioequivalence study comparing IV EPO zeta and EPO alfa

Krivoshiev 2010

RCT. Bioequivalence study comparing SC EPO zeta and EPO alfa

Linde 2001

Open‐label study investigated EPO alfa to reach normal haemoglobin or subnormal haemoglobin

Morris 1993

Did not compare early versus delayed EPO for the anaemia of ESKD

Muirhead 1992

Quasi‐RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Nissenson 1995

RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Parfrey 2005

RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Park 2014

RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Suzuki 1989

RCT; was short duration (8 weeks).

Trembecki 1995a

RCT; did not compare early versus delayed EPO for the anaemia of ESKD

Wizemann 2008

Bioequivalence study of IV erythropoietin zeta and erythropoietin alfa

Study flow diagram
Figuras y tablas -
Figure 1

Study flow diagram

Ir a la figura de la revisiónAbrir en una pestaña nueva